Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company is headquartered in Malvern, Pennsylvania.
| Revenue (TTM) | $155.10M |
| Gross Profit (TTM) | $76.59M |
| EBITDA | $-19.26M |
| Operating Margin | -3.61% |
| Return on Equity | -116.10% |
| Return on Assets | -10.50% |
| Revenue/Share (TTM) | $2.23 |
| Book Value | $0.32 |
| Price-to-Book | 10.10 |
| Price-to-Sales (TTM) | 1.08 |
| EV/Revenue | 1.591 |
| EV/EBITDA | -2.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 9.10% |
| Shares Outstanding | $77.73M |
| Float | $37.15M |
| % Insiders | 32.87% |
| % Institutions | 54.00% |
Volatility is currently expanding
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement awards to fourteen non-executive employees as described below.
Neuronetics NASDAQ: STIM reported third-quarter 2026 revenue growth, wider gross margin and a return to positive adjusted EBITDA, citing record NeuroStar system sales and continued revenue-cycle improvements across its Greenbrook clinic network.
Neuronetics (STIM) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.13 per share a year ago.
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced its financial and operating results for the third quarter of 2026.
MALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that it plans to release third quarter 2026 financial and operating results prior to market open on Wednesday, November 4, 2026.
MALVERN, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the integration of its TrakStar® practice management platform with AdvancedMD, a leading cloud-based electronic health record (EHR), practice management, and revenue cycle platform serving more than 65,000 practitioners across 13,000 independent practices in the ambulatory and mental health care space.
Neuronetics NASDAQ: STIM reported second-quarter 2026 revenue growth, a sharply narrower net loss and positive adjusted EBITDA as its Greenbrook clinic business expanded and the company introduced additional commercial purchasing options for its NeuroStar transcranial magnetic stimulation, or TMS, systems.
Neuronetics (STIM) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.15 per share a year ago.
MALVERN, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics” or the “Company”) and Jorey Chernett, the Company's second largest shareholder and Managing Member of Pointillist Family Office, today announced that they have created a constructive framework for alignment between the Company's Board of Directors (the “Board”), management, and Mr. Chernett (the “Understanding”).
MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement awards to five new non-executive employees as described below.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on STIM and any ticker you trade — then tracks every position and per-strategy win rate.
